Cervical cancer screening
What the major U.S. guidelines recommend, with a link to verify each at the source. A quick-reference summary for clinicians, not medical advice.
USPSTF · 2018 · Grade A
21–29: cytology q3y. 30–65: cytology q3y, OR hrHPV q5y, OR co-test q5y. <21: none. >65: stop if adequate prior screening.
Verify at USPSTF →ACS · 2025
Start at age 25; clinician- or self-collected primary HPV test q5y preferred through 65 (co-test q5y or cytology q3y acceptable). 2025 update adds self-collection and screening-exit guidance.
Verify at ACS →ASCCP / ACOG · 2021
Management of abnormal results per ASCCP risk-based guidelines; screening aligns with USPSTF/ACS.
Verify at ASCCP / ACOG →